Tectonic Therapeutic reported a net loss of $68.9 million for the nine months ended September 30, 2026, compared to $54.9 million in the prior year period, driven primarily by increased research and development expenses. The company maintained a strong cash position with $234.7 million in cash and cash equivalents as of the end of the third quarter.
Tectonic Therapeutic reported Q3 2026 financial results, ending the period with $234.7 million in cash which is expected to fund operations into Q1 2029. The company highlighted clinical progress, including favorable Phase 1a results for TX2100 and the dosing of the first patient in the Phase 2a ALPINE trial for TX45. Topline results for the APEX Phase 2 trial in PH-HFpEF are anticipated by the end of January 2027.
Term
Q3 2026
“The favorable safety, tolerability and PK results from the single ascending-dose portion of our TX2100 Phase 1a trial in healthy adult volunteers, together with FDA Fast Track designation for HHT and IND clearance for our Phase 1b trial, support our plans to evaluate TX2100 in patients with HHT.”
Alise Reicin, M.D., President and Chief Executive Officer
“We plan to initiate an open-label Phase 1b trial in patients with hematologic-support-dependent HHT by year-end 2026 and, in parallel, a placebo-controlled Phase 2 trial in patients with moderate-to-severe HHT in early 2027. We are also approaching a critical milestone for TX45, with topline results from our APEX Phase 2 trial in PH-HFpEF anticipated by the end of January 2027.”
Alise Reicin, M.D., President and Chief Executive Officer